Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.

Studied

Randomized comparison of semaglutide with placebo for symptoms, physical limitations and weight in obesity-related heart failure.

Who / model

529 people with obesity and heart failure with preserved ejection fraction; treatment lasted 52 weeks.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

Both primary outcomes improved more with semaglutide: the symptom/function score rose 16.6 versus 8.7 points, and weight fell 13.3% versus 2.6%. A secondary walking test improved by 21.5 versus 1.2 meters. Serious adverse events occurred in 13.3% versus 26.7%.

Limits

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary